Company & Sponsor Intelligence

Jazz Pharmaceuticals

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials16

Recruiting3

Completed10

Countries3

Therapeutic footprint

anxietyepilepsymultiple_sclerosisother_neurologyptsdschizophreniasleep_disorders

Indexed studies

NCT02091206A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
epilepsy · United StatesPHASE2

NCT02565108A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
epilepsy · SpainPHASE2

NCT05178316A Study of JZP150 in Adults With Posttraumatic Stress Disorder
ptsd · United StatesPHASE2

NCT05864846A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
epilepsy · United StatesPHASE4

NCT03406702CX-8998 for Absence Seizures
epilepsy · United StatesPHASE2

NCT05485831Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
epilepsy · ItalyACTIVE_NOT_RECRUITING

NCT02954887Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
other_neurology · United StatesPHASE3

NCT07723963A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
epilepsy · United StatesPHASE2, PHASE3

NCT02953548Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
other_neurology · United StatesPHASE3

NCT07728097A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
other_neurology · United StatesPHASE4

NCT02348606"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
other_neurology · United StatesPHASE3

NCT00106860A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
anxiety · United StatesPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →